Editorial Commentary: Neurocognitive Performance in Ritonavir-boosted Protease Inhibitor Monotherapy

Affiliations

¹ Department of Psychiatry, University of Toronto St. Michael's Hospital Centre for Research on Inner City Health, The Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.

Editorial

Adriana Carvalhal. Clin Infect Dis. 2016.

. 2016 Jul 15;63(2):265-7.

doi: 10.1093/cid/ciw281. Epub 2016 May 3.

¹ Department of Psychiatry, University of Toronto St. Michael's Hospital Centre for Research on Inner City Health, The Keenan Research Centre, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada.

No abstract available

Keywords: monotherapy; neurocognitive performance; protease inhibitor.

Comment on

Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.
Arenas-Pinto A, Stöhr W, Jäger HR, Haddow L, Clarke A, Johnson M, Chen F, Winston A, Godi C, Thust S, Trombin R, Cairns J, Solanky BS, Golay X, Paton NI; PIVOT Neurocognitive sub-study Team. Arenas-Pinto A, et al. Clin Infect Dis. 2016 Jul 15;63(2):257-64. doi: 10.1093/cid/ciw279. Epub 2016 May 3. Clin Infect Dis. 2016. PMID: 27143662 Free PMC article. Clinical Trial.